Literature DB >> 10521570

cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein.

P Malherbe1, J G Richards, H Gaillard, A Thompson, C Diener, A Schuler, G Huber.   

Abstract

The receptor for advanced glycation end products (RAGE) has been proposed as a cell surface receptor that binds amyloid-beta protein (Abeta), thereby triggering its cytotoxic effects [S.D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern, A.M. Schmidt, RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease, Nature 382 (1996) 685-691.]. A cDNA library of human lung was screened for RAGE with an appropriate hybridization probe. In addition to cell surface RAGE, one clone was found which encodes a new version of RAGE, termed hRAGEsec, which lacks the 19 amino acids of the membrane-spanning region and is therefore secreted. Comparison with the genomic sequence revealed that the synthesis of the secreted isoform requires alternative splicing. The deduced protein sequence of the mature hRAGEsec consists of 321 amino acids with a predicted molecular mass of 35.66 kDa. The pattern of expression of hRAGEsec in human brain was analyzed by in situ hybridization histochemistry. The most intense expression of the gene in contrast to cell surface RAGE was detected in hippocampal CA3 pyramidal cells, dentate gyrus granule cells, cortical neurons as well as glial cells in white matter. To investigate the interaction between Abeta and RAGE and another scavenger receptor, SRA, under physiological conditions, they were co-expressed with human betaAPP(695)-SFAD in a human cell and the level of Abeta in the condition medium was assessed by immunoprecipitation and enzyme-linked immunosorbent assay (ELISA) analysis. A nearly 100% reduction of Abeta from the conditioned medium of hRAGE cells and approximately 40% reduction from the SRA-cells implied that hRAGE could be a prominent cell surface receptor interacting with Abeta.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521570     DOI: 10.1016/s0169-328x(99)00174-6

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  41 in total

1.  Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans.

Authors:  Mitchell J Cohen; Michel Carles; Karim Brohi; Carolyn S Calfee; Pamela Rahn; Mariah S Call; Brian B Chesebro; Michael A West; Jean-François Pittet
Journal:  J Trauma       Date:  2010-06

2.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.

Authors:  Hideto Yonekura; Yasuhiko Yamamoto; Shigeru Sakurai; Ralica G Petrova; Md Joynal Abedin; Hui Li; Kiyoshi Yasui; Masayoshi Takeuchi; Zenji Makita; Shin Takasawa; Hiroshi Okamoto; Takuo Watanabe; Hiroshi Yamamoto
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

3.  Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren's syndrome.

Authors:  Carol Stewart; Seunghee Cha; Robert M Caudle; Kathleen Berg; Joseph Katz
Journal:  Rheumatol Int       Date:  2008-01-30       Impact factor: 2.631

4.  Acute hyperglycemic exacerbation of lung ischemia-reperfusion injury is mediated by receptor for advanced glycation end-products signaling.

Authors:  Damien J Lapar; Vanessa A Hajzus; Yunge Zhao; Christine L Lau; Brent A French; Irving L Kron; Ashish K Sharma; Victor E Laubach
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-06       Impact factor: 6.914

5.  Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?

Authors:  Josephine M Forbes; Georgia Soldatos; Merlin C Thomas
Journal:  Clin Biochem Rev       Date:  2005-11

6.  Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE).

Authors:  Lana E Hanford; Jan J Enghild; Zuzana Valnickova; Steen V Petersen; Lisa M Schaefer; Todd M Schaefer; Todd A Reinhart; Tim D Oury
Journal:  J Biol Chem       Date:  2004-09-20       Impact factor: 5.157

7.  Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.

Authors:  Ayumi Yoshizaki; Kazuhiro Komura; Yohei Iwata; Fumihide Ogawa; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Shinichi Sato
Journal:  J Clin Immunol       Date:  2008-09-30       Impact factor: 8.317

8.  Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.

Authors:  Hidenori Koyama; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Biomark Insights       Date:  2007-09-17

9.  The S100B/RAGE Axis in Alzheimer's Disease.

Authors:  Estelle Leclerc; Emmanuel Sturchler; Stefan W Vetter
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-21

10.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.